Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Lowered to “Sell” Rating by Wall Street Zen

Posted by Linda Flegge on Oct 19th, 2025

Wall Street Zen cut shares of Inspira Technologies OXY B.H.N. (NASDAQ:IINN – Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Separately, Weiss Ratings assumed coverage on Inspira Technologies OXY B.H.N. in a research note on Thursday, October 9th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.00.

View Our Latest Research Report on IINN

Inspira Technologies OXY B.H.N. Stock Down 1.8%

Inspira Technologies OXY B.H.N. stock opened at $1.10 on Friday. The stock’s 50 day moving average is $1.21 and its 200 day moving average is $0.96. The company has a quick ratio of 0.90, a current ratio of 1.15 and a debt-to-equity ratio of 0.27. Inspira Technologies OXY B.H.N. has a one year low of $0.40 and a one year high of $1.65.

Institutional Investors Weigh In On Inspira Technologies OXY B.H.N.

A hedge fund recently raised its stake in Inspira Technologies OXY B.H.N. stock. Virtu Financial LLC grew its position in shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Free Report) by 254.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,015 shares of the company’s stock after acquiring an additional 33,749 shares during the quarter. Virtu Financial LLC owned about 0.37% of Inspira Technologies OXY B.H.N. worth $31,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.72% of the company’s stock.

About Inspira Technologies OXY B.H.N.

(Get Free Report)

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.